EfficacyIncluded studies
There is limited evidence suggesting a difference favouring clomipramine over placebo on reducing obsessive-compulsive symptoms as measured by the Children's Y-BOCS (K = 1; N = 16; SMD = 20.94; 95% CI, 21.99 to 0.11). IMARCH1990
Tolerability
The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between clomipramine and placebo on the tolerability of treatment.DEVEAUGHGEISS1992
MARCH1990

From: 6, PHARMACOLOGICAL INTERVENTIONS

Cover of Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
NICE Clinical Guidelines, No. 31.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2006.
Copyright © 2006, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.